adesso (ADN1) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
15 Nov, 2025Executive summary
Achieved 13% year-over-year revenue growth for both Q3 and the nine-month period, reaching €1,084.1 million after nine months, with Q3 revenue at €374.6 million.
EBITDA rose 17% to €77.9 million for the nine months, with Q3 contributing €40.8 million and a margin of 10.9%.
Earnings per share improved by 519% to €0.99 for the first nine months.
Employee count increased by 9% to over 11,100, with 44% of growth abroad, mainly at SmartShore locations.
Sustained sales and EBITDA growth at 10-year CAGRs of 24% and 26%, respectively.
Financial highlights
Gross profit after nine months rose 10% to €913.2 million; personnel expenses increased 11% to €736.1 million.
Earnings before taxes increased from €7.3 million to €12.9 million; tax quota at 52%.
Free cash flow for nine months was €-69.4 million, mainly reflecting increased working capital.
Net cash position at the end of Q3 was €-135.5 million, with cash and cash equivalents at €45.2 million.
Equity ratio declined to 22.8% from 26.1% a year earlier.
Outlook and guidance
Full-year sales expected near the upper end of €1.35–1.45 billion, with EBITDA forecasted at €105–125 million.
EBITDA margin target for the year is 8%+, with a long-term goal of 11–13%.
One additional working day in Q4 2025 is expected to support further earnings growth.
Q4 expected to bring necessary sales and EBITDA to achieve guidance, though Q4 EBITDA may be slightly lower than Q3 due to seasonality.
Latest events from adesso
- Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025